课题基金 / 基金详情

131I-LYM-1 AT A DOSE OF 80MCI/M2 IN THE TREATMENT OF REFRACTORY B-CELL LYMPHOMA

131I-LYM-1 AT A DOSE OF 80MCI/M2 IN THE TREATMENT OF REFRACTORY B-CELL LYMPHOMA
80MCI/M2 剂量的 131I-LYM-1 治疗难治性 B 细胞淋巴瘤
批准号：
5218014
负责人：
RICHARD T SILVER
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5218014
关键词：
B lymphocyte antibody formation clinical research drug adverse effect human subject human therapy evaluation iodine neoplasm /cancer radionuclide therapy nonHodgkin's lymphoma radiation therapy dosage radionuclides

项目摘要

项目成果

RICHARD T SILVER的其他基金

相似基金

相关文献

中文摘要
翻译
确定I-131-LYM-1作为抢救疗法的有效性 消除和减少中间体受试者中可检测到的肿瘤 对电流不耐药的高级别b细胞性非霍奇金淋巴瘤 急救或挽救化疗并评价其安全性。 全身应用I-131-Lym-1的发病率和严重程度 不良反应、人类抗鼠抗体(HAMA)的发展，以及 毒性。
英文摘要
Determine the effectiveness of I-131-LYM-1 as a salvage therapy in eliminating and reducing detectable tumor in subjects with intermediate to high-grade b-cell non-Hodgkin's lymphoma who are refractory to current firstline or salvage chemotherapy and to evaluate the safety of systemically administered I-131-LYM-1 in terms of incidence and severity of adverse reactions, human anti-mouse antibody (HAMA) development, and toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STEM CELL RESCUE AFTER BONE MARROW CURETTAGE FOR TREATMENT OF AMM
131I-LYM-1 AT A DOSE OF 80MCI/M2 IN THE TREATMENT OF REFRACTORY B-CELL LYMPHOMA
131I-LYM-1 AT A DOSE OF 80MCI/M2 IN THE TREATMENT OF REFRACTORY B-CELL LYMPHOMA
CANCER AND LEUKEMIA GROUP B
海外基金